On March 21, 2022 AnHeart Therapeutics ("AnHeart"), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, reported a poster presentation for ROS1 inhibitor taletrectinib at the European Lung Cancer Congress 2022, held in Prague, Czech Republic, and virtually, March 30-April 2, 2022 (Press release, AnHeart Therapeutics, MAR 21, 2022, View Source [SID1234610489]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are below:

Poster Presentation Title: TRUST-II: A Global Phase II Study for Taletrectinib in ROS1 fusion Positive Lung Cancer and other solid tumors.

Presenter: Misako Nagasaka, M.D. Ph.D., University of California (UC) Irvine, School of Medicine.

Date/Time: The e-Posters will be available on the virtual platform of the ELCC website, in the e-Posters section, as of 29 March at 12:00 CEST.

"Taletrectinib is a next-generation, brain-penetrant, ROS1 inhibitor, and there is a high unmet medical need for lung cancer patients with this specific type of ROS1 fusions," said Dr. Misako Nagasaka, Associate Clinical Professor and Thoracic Oncologist, UC Irvine. "The results from the Phase 2 trial evaluating taletrectinib in patients with ROS1 fusions, in particular the compound’s ability to penetrate the blood-brain barrier is impressive and I look forward to participating in this program."

"We’re excited to present the poster at ELCC 2022, a major medical conference, and look forward to sharing additional data from the ongoing Phase 2 trial and bringing hope to patients with ROS1 fusion-positive NSCLC," said CEO Junyuan (Jerry) Wang, Ph.D., CEO & Co-Founder, AnHeart Therapeutics.

About TRUST-II Study

TRUST-II study (NCT04919811) is a phase 2, global, multicenter, open-label, single-arm multi-cohort study evaluating the efficacy and safety of taletrectinib for ROS1 fusion-positive advanced metastatic NSCLC and other solid tumors. Taletrectinib will be given at 600 mg once daily in 21-day cycle. The patients with ROS1 fusions detected by local tests are eligible to enroll with retrospective confirmation by a central laboratory. The study consists of four cohorts: cohort 1: systemic chemotherapy naïve or ≤ one prior line and ROS1 TKI naïve NSCLC (N=53); cohort 2: previously treated with one ROS1 TKI (crizotinib or entrectinib) and with progression who are either chemotherapy naïve or ≤ one line of platinum and/or pemetrexed based therapy for NSCLC (N=46); cohort 3: ≤ 2 prior ROS1 TKIs and with progression who are either chemotherapy naïve or ≤ 2 lines of platinum and/or pemetrexed based therapy for NSCLC (N=10); and cohort 4: systemic chemotherapy naïve or ≤ 2 prior lines of chemotherapy, but ROS1-TKI naïve ROS1 positive solid tumor other than NSCLC ( N=10). The primary endpoint is objective response rate (ORR) (RECIST v1.1) by independent review committee (IRC) assessment for cohorts 1 and 2. Key secondary endpoints include IRC-assessed duration of response, IRC-assessed intra-cranial ORR, progression free survival (PFS), overall survival (OS), and safety. This study is currently recruiting in Japan, Republic of Korea, and USA. Additional accrual is planned in Canada, China, and European Union.

About Taletrectinib

Taletrectinib is a novel best-in-class next-generation ROS1 inhibitor designed to effectively target ROS1 fusions with potential to treat both TKI-naïve and pre-treated patients. ROS1 rearrangement is estimated to be an oncogenic driver in approximately 1 to 2 percent of patients with NSCLC. ROS1 fusions are also observed in several other cancers such as cholangiocarcinoma, glioblastoma, ovarian, gastric, and colorectal cancers. Taletrectinib has demonstrated excellent potency against crizotinib resistance, good brain penetration and intracranial antitumor activity, and favorable safety profiles in ROS1 fusion-positive NSCLC patients. In these patients, few neurological adverse effects were observed, which likely benefits from the selective inhibition of ROS1 over TRKB by taletrectinib. More information about the ongoing China TRUST (Taletrectinib ROS1 LUng STudy) phase 2 trial and the global TRUST-II phase 2 trial may be found by searching clinical trial identifiers NCT04395677 and NCT04919811, respectively at View Source For questions about the ongoing trials, please contact [email protected].

On March 21, 2022 Integrated DNA Technologies’ xGen NGS portfolio launch in December, MLL, the Munich Leukemia Laboratory, one of the leading research and diagnostic laboratories for leukemias and lymphomas, reported the global genomics solutions provider’s Align Program (Press release, INTEGRATED DNA TECHNOLOGIES, MAR 21, 2022, View Source [SID1234610488]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The addition of MLL bolsters the program’s roster of preferred sequencing providers who are united in a shared mission to advance genomics research. MLL’s extensive experience in the sequencing of exomes, genomes, and transcriptomes, coupled with IDT’s robust xGen portfolio of NGS solutions spanning library preparation, hybridization capture, amplicon sequencing, and library normalization, provides cutting-edge products and services to support researchers’ NGS workflow needs.

"Accelerating the next research discovery continues to drive the genomics industry, and unlocking efficiencies and breaking down barriers can be keys to success," said Rajan Kapadia, IDT’s VP of Global Sales and Marketing. "IDT builds meaningful partnerships with its Align Program members to open access to innovative NGS tools and technologies for the research community, and we’re proud to add MLL to our growing roster of preferred providers. Working in lockstep with our partners in science, together we can empower researchers and help advance their important work."

MLL is well known for its extremely high level of expertise in NGS, which it now offers with its sequencing label, MLLSEQ, to researchers beyond the healthcare system. MLLSEQ offers a wide range of sequencing experience and capacities from wet labs to informatics. Services span from genomes to exomes to RNA sequencing, along with detailed bioinformatic processing and visualization of the data generated.

"We are very pleased to be part of IDT’s Align Program as its first partner in Europe," said Manja Meggendorfer, head of molecular genetics at MLL. "Partnering with IDT to advance genomics research was an easy decision, as the company’s work uniquely aligns with our mission. As whole exome sequencing, RNA sequencing, and oncology translational research continue to grow in demand, we are excited to work alongside IDT to deliver the sequencing needs of the scientific community and look forward to the new discoveries to come."

IDT is a leader in gene reading, writing, and editing, and delivers innovative, high-performing NGS solutions to enable research and discovery. IDT’s comprehensive NGS offerings feature customization, complexity and scalability that break down barriers for scientists and provide them confidence in their results.

Launched in 2021, the IDT Align Program broadens access to services and solutions that help move genomics research forward. The program unites some of the most comprehensive genomic sequencing servicers in the world who are aligned in a shared mission of collaboration and dedicated to breaking down research barriers. Align Program members help to ensure accessibility of NGS tools and resources for researchers who need sequencing tailored to their specific research. For a list of members and program benefits, visit IDT Align | IDT (idtdna.com).

On March 21, 2022 Tempus, a leader in artificial intelligence and precision medicine, reported the launch of EDGE, an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers using a single hematoxylin and eosin stain (H&E) slide (Press release, Tempus, MAR 21, 2022, View Source [SID1234610487]). With access to over 50 petabytes of de-identified multimodal data, Tempus is developing AI models with the aim to identify patients who would benefit from additional testing and may qualify for targeted therapies, including those in clinical trials, earlier in their cancer care journey.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The model portfolio, called Tempus HistogenomicsTM, features digital pathology algorithms that are being developed to use a single, whole slide H&E image to predict the potential of biomarkers, such as microsatellite instability (MSI) or homologous recombination deficiency (HRD) status, in patients whose samples are not ordinarily sequenced.

Tempus is creating a network of pathology labs, called NAPA, across the country that can access the company’s growing portfolio of investigational AI models designed to identify patients that are more likely to have targetable biomarkers. In addition, Tempus is collaborating with some of the world’s leading pharmaceutical and biotech companies to leverage the EDGE platform and NAPA network to identify unique biomarkers and co-develop novel AI applications.

"We believe there is a unique opportunity to advance patient care by integrating digital pathology AI tools into our daily clinical practice," said Matthew Leavitt, MD, CEO of PathNet Labs, a national network of digital pathology practices. "This collaboration will carefully validate safe-use clinical applications of Tempus Histogenomics, directly comparing these algorithms with conventional ancillary testing methodologies while seeking to empower our pathologists with computational tools that can assist in identifying patients most likely to benefit from new therapies."

"EDGE is one of the many ways in which we will leverage our AI-enabled platform and library of multimodal data, including our diverse matched digital pathology and molecular datasets, to more effectively identify the right treatments for the right patients even earlier in their treatment journey," said Abdul Hamid Halabi, GM and SVP of Translational AI at Tempus. "This platform will bring actionable AI to pathologists’ fingertips and support them in identifying optimal therapeutic paths for patients, while also facilitating the discovery of new biomarkers for researchers developing new, targeted therapies."

In December 2021, Tempus announced a collaboration with the Data Science and Oncology teams at Janssen Research & Development LLC (Janssen) aimed at jointly creating algorithms intended to further patient pre-screening efforts for specific cancer indications, including biomarker-selected cohorts, for Janssen’s clinical trials. Tempus also announced a strategic collaboration with AstraZeneca last year, which intends to utilize Tempus’ AI-enabled platform and multimodal data to advance novel therapeutic programs across AstraZeneca’s diverse oncology pipeline.

On March 21, 2022 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, reported that the European Commission has granted Orphan Drug Designation to AU-011, its first VDC product candidate, for the treatment of uveal melanoma (Press release, Aura Biosciences, MAR 21, 2022, View Source [SID1234610486]). The designation of uveal melanoma includes choroidal melanoma as well as melanomas of the iris and the ciliary body. Choroidal melanoma represents approximately 90% of uveal melanomas.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"There are currently no approved drug therapies for the treatment of early-stage choroidal melanoma, and receiving Orphan Drug Designation from EMA underscores the unmet need that AU-011 could fill for patients with this life-threatening disease," said Mark De Rosch, Ph.D., Chief Operating Officer and Head of Regulatory Affairs. "We have alignment with U.S. and European agencies on our pivotal program and are on track to initiate this program before the end of 2022."

The European Commission grants Orphan Drug Designation for medicinal products intended to treat life-threatening or chronically debilitating conditions that affect fewer than five in 10,000 people in the European Union (EU) and when no satisfactory method of diagnosis, prevention, or treatment of the condition can be authorized. The designation provides certain benefits and incentives in the EU, including protocol assistance, fee reductions, and ten years of market exclusivity once the medicine is on the market.

AU-011 was previously granted Orphan Drug Designation for the treatment of uveal melanoma by the U.S. Food and Drug Administration.

About AU-011

AU-011 is a first-in-class virus-like drug conjugate (VDC) therapy in clinical development for the first line treatment of choroidal melanoma. The virus-like component of the VDC selectively binds unique heparin sulphate proteoglycans (HSPGs), which are modified and overexpressed on the tumor cell surface of malignant cells in the choroid and AU-011 delivers a potent cytotoxic drug that is activated with infrared light. Upon activation with an ophthalmic laser, the cytotoxic drug rapidly and specifically disrupts the cell membrane of malignant cells with a pro-immunogenic cell death that can activate the immune system generating long term anti-tumor immunity. The unique specificity of tumor binding by the VDC enables the preservation of key eye structures, which may allow for the potential of preserving patients’ vision and reducing other long-term complications of radiation treatment. AU-011 can be delivered using equipment commonly found in an ophthalmologist’s office and does not require a surgical procedure, pointing to a potentially less invasive, more convenient therapy for patients and physicians. AU-011 for the treatment of choroidal melanoma is currently in Phase 2 clinical development and the company plans to expand the clinical program into choroidal metastasis.

On March 21, 2022 Ixaka Ltd, an integrated cell and gene therapy company, reported an expansion of its IP portfolio to allow a broad range of applications for its polymeric targeted nanoparticle (TNP) gene delivery platform across multiple therapeutic areas (Press release, Ixaka, MAR 21, 2022, View Source [SID1234610485]). The extended IP enables the development of therapies encapsulating any cargo including mRNA, plasmids and adenovirus associated virus (AAV), and gene editing technologies as well as lentiviral vector-based therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ixaka’s TNP – composed of proprietary polymer capsule (‘OM-PBAE’ polymers (oligopeptide end-modified poly β-amino-ester polymers)) directed to specific cells through targeting agents attached the capsule (an aptamer-based targeting moiety) and cell targeted efficient transduction (use of lentiviral vector cell specific promoter). This targeting enables the targeted nanoparticles to be directed to specific cells allowing beneficial gene transduction to occur directly within a patient’s body. The technology is currently being applied as a gene delivery platform to generate CAR T-cell therapies in vivo for haematological malignancies, with the potential for improved efficacy and safety compared to similar products currently marketed or in development. The expanded IP allows for a broad range of cargos to be encapsulated providing greater flexibility to engineer new therapies which are optimized to specific diseases.

A new agreement extends the use of its OM-PBAE polymers for encapsulation of a broad range of cargos for use in any therapeutic area including mRNA, plasmids, and any other vectors in addition to lentiviral vectors and AAV.

The extension of the license agreement opens the door to expansion of Ixaka’s TNP platform, enabling the use of OM-PBAE polymers capsules to be used for delivery of numerous cargos with the choice of genetic modification technology tailored for each disease. Potential applications include drug delivery for oligonucleotides such as DNA, RNA and siRNA, plasmids, small molecules, and gene editing using tools such as CRISPR–Cas9, zinc finger or megaTALS – enabling Ixaka to broaden its therapeutic pipeline.

Joe Dupere, CEO at Ixaka, commented:

"This IP agreement further strengthens Ixaka’s rapidly growing IP portfolio, highlighting the pioneering nature and broad potential of our targeted nanoparticle technology. The platform is already showing great potential in generating CAR-T cells in vivo for CD19 blood cancers. With an array of other possible applications, we will now be seeking collaborations for our future pipeline, which could encompass solid tumours, rare genetic disorders, autoimmune diseases, broader immunotherapy applications, gene editing, immunodiagnostics and vaccines.

IP portfolio overview

Building a robust and broad IP portfolio is at the heart of Ixaka’s development strategy. The Company’s ongoing R&D and upcoming clinical data will allow filing of additional patent applications across multiple territories.

Ixaka’s current IP portfolio contains 1 patent family for its multi-cell therapy platform and 11 patent families for its TNP platform, covering all key components of the technology, including a proprietary polymer, bald engineered lentiviral vector, T-cell specific promoter and aptamer-based targeting agent. The portfolio also provides protection across a wide geographic range (including Europe, the US, Canada, Mexico, Brazil, China, India, Korea, Japan, Australia).

The patent is for products developed under a licence agreement between Ixaka (previously aratinga.bio), Sagetis Biotech ("Sagetis") and universities (Institut Quimic de Sarria CETS Fundacio Privada and Institut d’Investigacions Biomediques).